Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about APUS, unsubscribe in one click. Privacy
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Apitox - pure honeybee toxin | Multiple Sclerosis | Phase 3 · NCT03710655 | Unknown |
| Histamine | Osteoarthritis of the Knee | Phase 3 · NCT01112722 | Completed |
| honeybee venom (Apitoxin (Korea) Apitox | Osteoarthritis of the Knee | Phase 2 · NCT00949754 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
APUS holds $278,371 in cash and short-term investments (as of Jun 30, 2026) and burns about $3.9M/quarter from operations, an estimated runway of 0.2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 55 · Elevated
These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date these condensed consolidated financial statements are issued.10-Q, Aug 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when APUS files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Apimeds Inc. | 5%+ holder (13D) | 4,316,618 | 286.04% | 2026-05-07 |
| Inscobee Inc. 10% owner |
Insider | 2,099,747 | 139.14% | 2025-05-12 |
| Ayrton Capital LLC | Institution (13G, 5%+) | 1,397,021 | 92.57% | 2025-12-31 |
| Erik C. Emerson Chief Executive Officer, Director · +562,279 options |
Insider | 750,000 | 49.70% | 2025-05-16 |
| Jakap Koo Director · +18,780 options |
Insider | 643,885 | 42.67% | 2025-05-12 |
| Christopher Kim Chairman and CMO, Director · +3,000 options |
Insider | 277,500 | 18.39% | 2025-05-16 |
Share count 1,509,118 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for APUS and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →